Leveraging phased variants for personalized minimal residual disease detection in localized non-small cell lung cancer.

8518Background: Detection of circulating tumor DNA (ctDNA) has prognostic value in lung cancer and could facilitate minimal residual disease (MRD) driven approaches. However, the sensitivity of ctD...